[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632517":3},{"organization":4,"outcomesModule":7,"designInfo":54,"detailedDescription":56,"studyPopulation":57,"armGroups":58,"interventions":63,"overallOfficials":68,"centralContacts":76,"locations":82,"responsibleParty":491,"collaborators":53,"id":493,"slug":53,"hasResults":494,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":494,"sex":500,"minAge":501,"maxAge":53,"enrollmentInfo":502,"targetDuration":53,"studyType":505,"phases":53,"briefSummary":506,"conditions":507,"keywords":509,"overallStatus":515,"whyStopped":53,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":525},{"fullName":5,"class":6},"The Lymphoma Academic Research Organisation","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":53},[9],{"measure":10,"description":11,"timeFrame":12},"The primary endpoint is the proportion of participants for whom MRD results are delivered within these timelines at the predefined interim treatment response assessment.","The primary objective of the study is to assess the feasibility of providing investigators with MRD results for participants with previously untreated aggressive B cell lymphomas at the time of the predefined interim response assessment, within strict timelines:\n\n* no more than 14 calendar days from blood collection for ctDNA results, and\n* no more than 7 calendar days after the imaging examination for the centralized PET review results.","at interim timepoint, after Cycle 4 (each cycle is 14 or 21 days)",[14,18,21,24,27,30,32,34,36,40,42,46,50],{"measure":15,"description":16,"timeFrame":17},"Survival","Event Free Survival (EFS) by histology subtype","at 1 year",{"measure":19,"description":20,"timeFrame":17},"Progression\u002Frelapse","Duration of response (DoR) as defined by Lugano 2014 criteria",{"measure":22,"description":23,"timeFrame":17},"Evaluate the prognostic value of ctDNA\u002Fradiomics PET at mid-treatment and end-of-treatment","PFS according to ctDNA MRD status at the interim assessment and at the end of treatment assessment (positive vs negative), according to the interim PET response (response per Lugano 2014 and other radiomic parameters), and according to their combination (ctDNA + PET).",{"measure":25,"description":26,"timeFrame":12},"To document and classify the reasons for unsuccessful PET acquisition, analysis or reporting","Number of participants with delayed results, and reasons associated.",{"measure":15,"description":28,"timeFrame":29},"Progression-free survival (PFS) by histology subtype","1year",{"measure":15,"description":31,"timeFrame":29},"Overall Survival (OS) by histology subtype",{"measure":22,"description":33,"timeFrame":17},"EFS according to ctDNA MRD status at the interim assessment and at the end of treatment assessment (positive vs negative), according to the interim PET response (response per Lugano 2014 and other radiomic parameters), and according to their combination (ctDNA + PET).",{"measure":22,"description":35,"timeFrame":17},"OS according to ctDNA MRD status at the interim assessment and at the end of treatment assessment (positive vs negative), according to the interim PET response (response per Lugano 2014 and other radiomic parameters), and according to their combination (ctDNA + PET).",{"measure":37,"description":38,"timeFrame":39},"Number of participants with concordant results (positive PET and ctDNA or negative PET and ctDNA) and number of participants with discordant results (positive PET and negative ctDNA or negative PET and positive ctDNA).","Concordance rate between metabolic PET response and ctDNA result","Each timepoint (pre-treatment, interim timepoint, end of treatment)",{"measure":41,"description":26,"timeFrame":12},"To document and classify the reasons for unsuccessful ctDNA sampling, processing or result reporting.",{"measure":43,"description":44,"timeFrame":45},"To assess the proportion of informative cfDNA samples for phased variant monitoring","Proportion of samples with at least twenty phased variants detectable at baseline","Baseline",{"measure":47,"description":48,"timeFrame":49},"Describe the timelines for the delivery of the results of the centralized PET review.","Proportions of participants for whom results are delivered within the predefined time frame in the protocol (time between the date of image acquisition or collection and the date of transmission to the investigator ≤ target time), at baseline (before interim evaluation) and at the end of treatment (≤ 5 weeks) with a 95% confidence interval.\n\nThe observed delays (in calendar days) will also be described by their distribution (median, interquartile range, minimum-maximum)","Two timepoints (Baseline, end of treatment)",{"measure":51,"description":52,"timeFrame":49},"Describe the timelines for the delivery of the results of ctDNA results.","Proportions of participants for whom results are delivered within the predefined time frame in the protocol (time between the date of blood collection and the date of transmission to the investigator ≤ target time), at baseline (before interim evaluation) and at the end of treatment (≤ 5 weeks), estimated globally and by RT4 platform with a 95% confidence interval.\n\nThe observed delays (in calendar days) will also be described by their distribution (median, interquartile range, minimum-maximum), overall and by platform",null,{"allocation":53,"interventionModel":53,"interventionModelDescription":53,"primaryPurpose":53,"observationalModel":6,"timePerspective":55,"maskingInfo":53},"PROSPECTIVE","Monitoring measurable residual disease (MRD) through the analysis of circulating tumor DNA (ctDNA) in plasma is rapidly emerging as one of the major recent advances in the management of lymphomas. Over the past years, several studies have shown that ctDNA enables a dynamic and highly sensitive assessment of treatment response, surpassing the limitations of conventional approaches based on imaging only.\n\nImportantly, these advances do not replace or diminish the role of PET imaging. On the contrary, metabolic imaging and molecular monitoring are increasingly seen as complementary tools. When used together, PET imaging and ctDNA kinetic analysis may dynamically refine risk stratification and enable truly individualized adaptive treatment strategies. However, this synergy between MRD and PET can only influence clinical practice or trial design if results are available throughout patient management within a timeframe compatible with therapeutic decision making.","Participants with aggressive B cell lymphoma",[59],{"label":60,"type":53,"description":53,"interventionNames":61},"All participants will receive standard of care treatment only, according to local practice.",[62],"Other: blood test",[64],{"type":6,"name":65,"description":66,"armGroupLabels":67,"otherNames":53},"blood test","Three blood tests will be performed (one before treatment, one at mid treatment, and one at the end of treatment) for ctDNA analysis.",[60],[69,73],{"name":70,"affiliation":71,"role":72},"Vincent CAMUS, Dr","CENTRE HENRI BECQUEREL - Service Hématologie","PRINCIPAL_INVESTIGATOR",{"name":74,"affiliation":75,"role":72},"Cédric ROSSI, Pr","CHU DIJON BOURGOGNE - Service Hématologie Clinique",[77],{"name":78,"role":79,"phone":80,"phoneExt":53,"email":81},"Project Management Project Management","CONTACT","+33 (0) 4 27 01 27 22","RT4@lysarc.org",[83,100,114,128,142,156,170,183,197,211,225,239,250,264,278,292,306,320,331,342,353,367,381,395,409,423,436,450,464,478],{"facility":84,"status":53,"city":85,"state":53,"zip":86,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":94,"contacts":95},"CHU D'AMIENS - HOPITAL SUD - Service Hématologie Clinique et Thérapie Cellulaire","Amiens","80054","France","FR",{"type":90,"coordinates":91},"Point",[92,93],2.3,49.9,{"lat":93,"lon":92},[96],{"name":97,"role":79,"phone":98,"phoneExt":53,"email":99},"Dr. Caroline SKRZYPCZAK","+33 (0)3 22 45 59 14","skrzypczak.caroline@chu-amiens.fr",{"facility":101,"status":53,"city":102,"state":53,"zip":103,"country":87,"countryCode":88,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"CHU D'ANGERS - Service des Maladies du Sang","Angers","49033",{"type":90,"coordinates":105},[106,107],-0.55202,47.47156,{"lat":107,"lon":106},[110],{"name":111,"role":79,"phone":112,"phoneExt":53,"email":113},"Dr. Jérôme PAILLASSA","+33 (0)6 21 82 31 85","jerome.paillassa@chu-angers.fr",{"facility":115,"status":53,"city":116,"state":53,"zip":117,"country":87,"countryCode":88,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"CH D'AVIGNON - HOPITAL HENRI DUFFAUT - Service d'Onco-Hématologie","Avignon","84000",{"type":90,"coordinates":119},[120,121],4.80892,43.94834,{"lat":121,"lon":120},[124],{"name":125,"role":79,"phone":126,"phoneExt":53,"email":127},"Dr. Thierry TAKAM","+33 (0)4 32 75 93 78","takam.thierry@ch-avignon.fr",{"facility":129,"status":53,"city":130,"state":53,"zip":131,"country":87,"countryCode":88,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"CHU JEAN MINJOZ - Service Hématologie","Besançon","25030",{"type":90,"coordinates":133},[134,135],6.01815,47.24878,{"lat":135,"lon":134},[138],{"name":139,"role":79,"phone":140,"phoneExt":53,"email":141},"Dr. Adrien CHAUCHET","+33 (0)3 81 66 82 32","achauchet@chu-besancon.fr",{"facility":143,"status":53,"city":144,"state":53,"zip":145,"country":87,"countryCode":88,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique","Clermont-Ferrand","63003",{"type":90,"coordinates":147},[148,149],3.08682,45.77969,{"lat":149,"lon":148},[152],{"name":153,"role":79,"phone":154,"phoneExt":53,"email":155},"Dr. Sébastien BAILLY","+33 (0)4 73 75 00 65","s-bailly@chu-clermontferrand.fr",{"facility":157,"status":53,"city":158,"state":53,"zip":159,"country":87,"countryCode":88,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes","Créteil","94010",{"type":90,"coordinates":161},[162,163],2.46569,48.79266,{"lat":163,"lon":162},[166],{"name":167,"role":79,"phone":168,"phoneExt":53,"email":169},"Dr. François LEMONNIER","+33 (0)1 49 81 20 51","francois.lemonnier@aphp.fr",{"facility":75,"status":53,"city":171,"state":53,"zip":172,"country":87,"countryCode":88,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"Dijon","21000",{"type":90,"coordinates":174},[175,176],5.01391,47.31344,{"lat":176,"lon":175},[179],{"name":180,"role":79,"phone":181,"phoneExt":53,"email":182},"Pr. Cédric ROSSI","+33 (0)6 80 29 50 41","cedric.rossi@chu-dijon.fr",{"facility":184,"status":53,"city":185,"state":53,"zip":186,"country":87,"countryCode":88,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"CHD DE VENDEE - Service Hématologie","La Roche-sur-Yon","85925",{"type":90,"coordinates":188},[189,190],-1.42757,46.66974,{"lat":190,"lon":189},[193],{"name":194,"role":79,"phone":195,"phoneExt":53,"email":196},"Dr. Antoine LEVEQUE","+33 (0)2 51 44 61 73","antoine.leveque@ght85.fr",{"facility":198,"status":53,"city":199,"state":53,"zip":200,"country":87,"countryCode":88,"cosmosGeoPoint":201,"geoPoint":205,"contacts":206},"CHU DE GRENOBLE - Service Hématologie","La Tronche","38700",{"type":90,"coordinates":202},[203,204],5.74629,45.20507,{"lat":204,"lon":203},[207],{"name":208,"role":79,"phone":209,"phoneExt":53,"email":210},"Dr. Sylvain CARRAS","+33 (0)4 76 76 57 55","scarras@chu-grenoble.fr",{"facility":212,"status":53,"city":213,"state":53,"zip":214,"country":87,"countryCode":88,"cosmosGeoPoint":215,"geoPoint":219,"contacts":220},"CH DE VERSAILLES - HOPITAL ANDRE MIGNOT - Service Hématologie Adolescents et Jeunes Adultes","Le Chesnay","78157",{"type":90,"coordinates":216},[217,218],2.12213,48.8222,{"lat":218,"lon":217},[221],{"name":222,"role":79,"phone":223,"phoneExt":53,"email":224},"Dr. Aurélie CABANNES-HAMY","+33 (0)1 39 63 90 33","acabannes@ght78sud.fr",{"facility":226,"status":53,"city":227,"state":53,"zip":228,"country":87,"countryCode":88,"cosmosGeoPoint":229,"geoPoint":233,"contacts":234},"HOPITAL SAINT VINCENT-DE-PAUL - Service Hématologie Clinique","Lille","59020",{"type":90,"coordinates":230},[231,232],3.05512,50.63391,{"lat":232,"lon":231},[235],{"name":236,"role":79,"phone":237,"phoneExt":53,"email":238},"Dr. Sandy AMORIM","+33 03 20 87 45 32","amorim.sandy@ghicl.net",{"facility":240,"status":53,"city":227,"state":53,"zip":241,"country":87,"countryCode":88,"cosmosGeoPoint":242,"geoPoint":244,"contacts":245},"CHU DE LILLE - HOPITAL CLAUDE HURIEZ - Service des Maladies du Sang","59037",{"type":90,"coordinates":243},[231,232],{"lat":232,"lon":231},[246],{"name":247,"role":79,"phone":248,"phoneExt":53,"email":249},"Pr. Franck MORSCHHAUSER","+33 (0)3 20 44 57 13","franck.morschhauser@chu-lille.fr",{"facility":251,"status":53,"city":252,"state":53,"zip":253,"country":87,"countryCode":88,"cosmosGeoPoint":254,"geoPoint":258,"contacts":259},"CENTRE LEON BERARD - Service Hématologie","Lyon","69373",{"type":90,"coordinates":255},[256,257],4.84789,45.74906,{"lat":257,"lon":256},[260],{"name":261,"role":79,"phone":262,"phoneExt":53,"email":263},"Dr. Sylvain LAMURE","+33 (0)4 69 85 61 93","sylvain.lamure@lyon.unicancer.fr",{"facility":265,"status":53,"city":266,"state":53,"zip":267,"country":87,"countryCode":88,"cosmosGeoPoint":268,"geoPoint":272,"contacts":273},"CHU DE MONTPELLIER - Département d'Hématologie Clinique","Montpellier","34295",{"type":90,"coordinates":269},[270,271],3.87635,43.61093,{"lat":271,"lon":270},[274],{"name":275,"role":79,"phone":276,"phoneExt":53,"email":277},"Dr. Charles HERBAUX","+33 (0)4 67 33 83 64","c-herbaux@chu-montpellier.fr",{"facility":279,"status":53,"city":280,"state":53,"zip":281,"country":87,"countryCode":88,"cosmosGeoPoint":282,"geoPoint":286,"contacts":287},"CHU DE NANTES - Service Hématologie","Nantes","44093",{"type":90,"coordinates":283},[284,285],-1.55336,47.21725,{"lat":285,"lon":284},[288],{"name":289,"role":79,"phone":290,"phoneExt":53,"email":291},"Dr. Benoit TESSOULIN","+33 (0)2 40 08 32 71","benoit.tessoulin@chu-nantes.fr",{"facility":293,"status":53,"city":294,"state":53,"zip":295,"country":87,"countryCode":88,"cosmosGeoPoint":296,"geoPoint":300,"contacts":301},"CHU ORLEANS - Service Oncologie Médicale","Orléans","45067",{"type":90,"coordinates":297},[298,299],1.90407,47.90248,{"lat":299,"lon":298},[302],{"name":303,"role":79,"phone":304,"phoneExt":53,"email":305},"Dr. Marlène OCHMANN","+33 (0)2 38 57 52 54","marlene.ochmann@chu-orleans.fr",{"facility":307,"status":53,"city":308,"state":53,"zip":309,"country":87,"countryCode":88,"cosmosGeoPoint":310,"geoPoint":314,"contacts":315},"HOPITAL COCHIN - Hématologie clinique","Paris","75014",{"type":90,"coordinates":311},[312,313],2.3488,48.85341,{"lat":313,"lon":312},[316],{"name":317,"role":79,"phone":318,"phoneExt":53,"email":319},"Dr. Loïc RENAUD","+33 (0)1 42 11 45 07","loic.renaud@aphp.fr",{"facility":321,"status":53,"city":308,"state":53,"zip":322,"country":87,"countryCode":88,"cosmosGeoPoint":323,"geoPoint":325,"contacts":326},"HOPITAL SAINT-LOUIS - Service Hématologie Adolescents et Jeunes Adultes","75475",{"type":90,"coordinates":324},[312,313],{"lat":313,"lon":312},[327],{"name":328,"role":79,"phone":329,"phoneExt":53,"email":330},"Dr. Florian CHEVILLON","+ 33 01 42 38 51 27","florian.chevillon@aphp.fr",{"facility":332,"status":53,"city":308,"state":53,"zip":333,"country":87,"countryCode":88,"cosmosGeoPoint":334,"geoPoint":336,"contacts":337},"HOPITAL DE LA PITIE SALPETRIERE - Service Hématologie Clinique","75651",{"type":90,"coordinates":335},[312,313],{"lat":313,"lon":312},[338],{"name":339,"role":79,"phone":340,"phoneExt":53,"email":341},"Dr. Daphné KRZISCH","+33 (0)1 84 82 84 94","daphne.krzisch@aphp.fr",{"facility":343,"status":53,"city":308,"state":53,"zip":344,"country":87,"countryCode":88,"cosmosGeoPoint":345,"geoPoint":347,"contacts":348},"HOPITAL NECKER - Service Hématologie Adultes","75743",{"type":90,"coordinates":346},[312,313],{"lat":313,"lon":312},[349],{"name":350,"role":79,"phone":351,"phoneExt":53,"email":352},"Dr. Morgane CHEMINANT","+33 (0)1 44 49 52 83","morgane.cheminant@aphp.fr",{"facility":354,"status":53,"city":355,"state":53,"zip":356,"country":87,"countryCode":88,"cosmosGeoPoint":357,"geoPoint":361,"contacts":362},"CHU DE BORDEAUX - HOPITAL HAUT-LEVEQUE - CENTRE FRANCOIS MAGENDIE - Service d'Hématologie et Thérapie Cellulaire","Pessac","33604",{"type":90,"coordinates":358},[359,360],-0.6324,44.80565,{"lat":360,"lon":359},[363],{"name":364,"role":79,"phone":365,"phoneExt":53,"email":366},"Dr. François-Xavier GROS","+33 (0)5 57 65 65 11","francois-xavier.gros@chu-bordeaux.fr",{"facility":368,"status":53,"city":369,"state":53,"zip":370,"country":87,"countryCode":88,"cosmosGeoPoint":371,"geoPoint":375,"contacts":376},"CHU LYON-SUD - Hématologie Clinique","Pierre-Bénite","69495",{"type":90,"coordinates":372},[373,374],4.82424,45.70359,{"lat":374,"lon":373},[377],{"name":378,"role":79,"phone":379,"phoneExt":53,"email":380},"Dr. Pierre SESQUES","+33 (0)4 78 86 43 46","pierre.sesques@chu-lyon.fr",{"facility":382,"status":53,"city":383,"state":53,"zip":384,"country":87,"countryCode":88,"cosmosGeoPoint":385,"geoPoint":389,"contacts":390},"CHU DE POITIERS - HOPITAL DE LA MILETRIE - Service d'Oncologie Hématologique et Thérapie Cellulaire","Poitiers","86021",{"type":90,"coordinates":386},[387,388],0.34348,46.58261,{"lat":388,"lon":387},[391],{"name":392,"role":79,"phone":393,"phoneExt":53,"email":394},"Dr. Stéphanie GUIDEZ","fr +33 (0)5 49 44 43 07","stephanie.guidez@chu-poitiers.fr",{"facility":396,"status":53,"city":397,"state":53,"zip":398,"country":87,"countryCode":88,"cosmosGeoPoint":399,"geoPoint":403,"contacts":404},"CHU DE REIMS - HOPITAL ROBERT DEBRE - Service Hématologie","Reims","51092",{"type":90,"coordinates":400},[401,402],4.02853,49.26526,{"lat":402,"lon":401},[405],{"name":406,"role":79,"phone":407,"phoneExt":53,"email":408},"Dr. Eric DUROT","+33 (0)6 64 77 25 61","edurot@chu-reims.fr",{"facility":410,"status":53,"city":411,"state":53,"zip":412,"country":87,"countryCode":88,"cosmosGeoPoint":413,"geoPoint":417,"contacts":418},"CHU PONTCHAILLOU - Hématologie Clinique","Rennes","35033",{"type":90,"coordinates":414},[415,416],-1.67431,48.11109,{"lat":416,"lon":415},[419],{"name":420,"role":79,"phone":421,"phoneExt":53,"email":422},"Pr. Roch HOUOT","+33 (0)2 99 28 98 73","roch.houot@chu-rennes.fr",{"facility":71,"status":53,"city":424,"state":53,"zip":425,"country":87,"countryCode":88,"cosmosGeoPoint":426,"geoPoint":430,"contacts":431},"Rouen","76038",{"type":90,"coordinates":427},[428,429],1.09932,49.44313,{"lat":429,"lon":428},[432],{"name":433,"role":79,"phone":434,"phoneExt":53,"email":435},"Dr. Vincent CAMUS","+33 (0)2 32 08 29 47","vincent.camus@chb.unicancer.fr",{"facility":437,"status":53,"city":438,"state":53,"zip":439,"country":87,"countryCode":88,"cosmosGeoPoint":440,"geoPoint":444,"contacts":445},"INSTITUT CURIE - SITE SAINT-CLOUD - Service Hématologie","Saint-Cloud","92210",{"type":90,"coordinates":441},[442,443],2.20289,48.84598,{"lat":443,"lon":442},[446],{"name":447,"role":79,"phone":448,"phoneExt":53,"email":449},"Dr. Adrien GILBERT","+33 (0)1 47 11 15 15","adrien.gilbert@curie.fr",{"facility":451,"status":53,"city":452,"state":53,"zip":453,"country":87,"countryCode":88,"cosmosGeoPoint":454,"geoPoint":458,"contacts":459},"IUCT ONCOPOLE - Service Hématologie","Toulouse","31059",{"type":90,"coordinates":455},[456,457],1.44367,43.60426,{"lat":457,"lon":456},[460],{"name":461,"role":79,"phone":462,"phoneExt":53,"email":463},"Dr. Lucie OBERIC","+33 (0)5 61 77 20 78","oberic.lucie@iuct-oncopole.fr",{"facility":465,"status":53,"city":466,"state":53,"zip":467,"country":87,"countryCode":88,"cosmosGeoPoint":468,"geoPoint":472,"contacts":473},"CHRU NANCY - HÔPITAL BRABOIS - Service Hématologie","Vandœuvre-lès-Nancy","54511",{"type":90,"coordinates":469},[470,471],6.17114,48.66115,{"lat":471,"lon":470},[474],{"name":475,"role":79,"phone":476,"phoneExt":53,"email":477},"Pr. Pierre FEUGIER","+33 (0)3 83 15 32 57","p.feugier@chru-nancy.fr",{"facility":479,"status":53,"city":480,"state":53,"zip":481,"country":87,"countryCode":88,"cosmosGeoPoint":482,"geoPoint":486,"contacts":487},"GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique","Villejuif","94085",{"type":90,"coordinates":483},[484,485],2.35992,48.7939,{"lat":485,"lon":484},[488],{"name":489,"role":79,"phone":318,"phoneExt":53,"email":490},"Dr. Vincent RIBRAG","vincent.ribrag@gustaveroussy.fr",{"type":492,"investigatorFullName":53,"investigatorTitle":53,"investigatorAffiliation":53,"oldNameTitle":53,"oldOrganization":53},"SPONSOR","100632517",false,"NCT07514715","Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas","Proof of Concept for Real-time Multicentric Monitoring of Minimal Residual Disease (MRD) by PET and Circulating Tumor DNA (ctDNA) in Aggressive B-Cell Lymphomas","RT4","Inclusion criteria\n\nParticipants must meet all of the following criteria to be included in the study:\n\n1. Participant who understands and voluntarily signs an informed consent form prior to any study-specific assessment or procedure.\n2. Age 18 or older at the time of signing the Informed Consent Form (ICF)\n3. Histologically confirmed diagnosis, according to the WHO 2022 classification, of any of the following lymphomas:\n\n   Aggressive B-cell lymphoma, including:\n   * Diffuse large B-cell lymphoma, unspecified (DLBCL not specified)\n   * High-grade B-cell lymphoma (LBHG), including:\n\n     1. With rearrangements of the MYC and BCL2 and\u002For BCL6 genes (double\u002Ftriple hit)\n     2. Unspecified (i.e., no double\u002Ftriple rearrangement)\n   * Primary B-cell lymphoma of the mediastinum (PMBL)\n   * Transformed indolent B-cell lymphoma, including:\n\n     1. Transformed follicular lymphoma (LFt)\n     2. Transformed marginal zone lymphoma (t-MZL)\n     3. Transformed, unspecified nodal or splenic B-cell lymphomas (NOS)\n4. Presence of a measurable disease on pre-therapeutic PET imaging, defined as at least one two-dimensional measurable nodal lesion, defined as \\> 1.5 cm in its largest dimension (and FDG-greedy lesion), or at least one two-dimensional measurable extranodal lesion, defined as \\> 1.0 cm in its largest dimension (and FDG-hungry lesion).\n5. Requiring standard first-line systemic treatment with curative intent\n6. Person covered by a social security scheme\n7. Person able to understand and speak French. Exclusion criteria\n\nParticipants who meet any of the criteria below will not be eligible for inclusion \u002F should be excluded from the study:\n\n1. Systemic anticancer treatment of current lymphoma prior to inclusion in the study. All participants must be previously untreated for current lymphoma.\n\n   Note: Short-term corticosteroid therapy (e.g., for symptom control or as part of diagnostic workup) is allowed prior to inclusion and is not an exclusion criterion.\n2. Lymphomas associated with an immuno-privileged site (e.g., primary central nervous system lymphoma, primary testicular lymphoma, primary vitreoretinal lymphoma).\n3. Absence of mandatory blood sampling for the analysis of circulating tumor DNA (ctDNA) during screening (pre-therapeutic sampling).\n4. Absence of 18F-FDG PET examination performed within 2 months ≤ the date of signing the consent (mandatory pre-therapeutic PET imaging).\n5. Pregnant, intending to be pregnant, or breastfeeding woman of childbearing potential\n6. Any significant medical condition, laboratory abnormality, or psychiatric illness that may interfere with participation in this clinical study (in the opinion of the investigator)\n7. Person deprived of liberty by judicial or administrative decision\n8. Person hospitalized without their consent\n9. Adult under legal protection","ALL","18 Years",{"count":503,"type":504},129,"ESTIMATED","OBSERVATIONAL","RT4 (REAL TIME TAILORED THERAPY) study was designed as a national, multicenter proof of concept aiming to demonstrate the technical and operational capacity of the French Connect network and the Positron Emission Tomography (PET) review network to ensure, within a coordinated framework, real time MINIMAL RESIDUAL DISEASE (MRD) monitoring through ctDNA analysis and centralized review of PET imaging.",[508],"Aggressive B-cell Lymphomas",[510,511,512,513,514],"Circulating Tumor DNA","Measurable Residual Disease","Large B-Cell Lymphoma","PhasED-Seq","PET-Scan in Lymphoma","NOT_YET_RECRUITING","2026-06-09",{"date":518,"type":519},"2026-06-11","ACTUAL",{"date":521,"type":504},"2026-06-30",{"date":523,"type":504},"2028-10-01",{"name":5,"class":6},30]